Viatris Inc (VTRS)vsZhengye Biotechnology Holding Limited Ordinary Shares (ZYBT)
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
ZYBT
Zhengye Biotechnology Holding Limited Ordinary Shares
$0.88
+1.06%
HEALTHCARE · Cap: $41.21M
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 9202% more annual revenue ($14.30B vs $153.74M). ZYBT leads profitability with a -12.6% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).
VTRS
Buy50
out of 100
Grade: C-
ZYBT
Avoid26
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Reasonable price relative to book value
Areas to Watch
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Smaller company, higher risk/reward
ROE of -6.4% — below average capital efficiency
Revenue declined 34.4%
Earnings declined 79.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bull Case : ZYBT
The strongest argument for ZYBT centers on Price/Book.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Bear Case : ZYBT
The primary concerns for ZYBT are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
VTRS is growing revenue faster at 5.0% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VTRS scores higher overall (50/100 vs 26/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Zhengye Biotechnology Holding Limited Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zhengye Biotechnology Holding Limited (Ticker: ZYBT) is an innovative biotechnology firm focused on the development and commercialization of advanced biopharmaceutical products. The company leverages its proprietary technologies and a diverse product pipeline to address critical medical needs, positioning itself strategically to enhance treatment outcomes across multiple therapeutic areas. With a robust commitment to research and development, ZYBT aims to drive significant growth and deliver substantial value to its investors, while maintaining a strong emphasis on quality and innovation within the dynamic biotechnology landscape.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?